Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety of brexpiprazole 1 mg or 2 mg after a 14 week treatment regimen for
agitation associated with dementia of the Alzheimer's type patients who completed in a
double-blind trial, and to investigate the efficacy of brexpiprazole.